Darryl Sleep on Collaboration and Partnership Across the Entire HHT Community: Patients Can’t Wait!
Darryl Sleep, Former Head Global Public Health at Amgen, BioPharma Executive, reposted from Azmi Nabulsi on LinkedIn:
”I am honored to be part of a dedicated team committed to developing focused, targeted therapeutics to address significant unmet medical need patients living with HHT.
The collaboration and partnership across the entire HHT community of researchers, academics, patient advocacy, patients and caregivers is truly inspiring.
All stakeholders work together with urgency and a deep commitment to improve the lives patients living with HHT.
Patients can’t wait!”
Quoting Azmi Nabulsi‘s post:
”It’s a proud moment for our team to see the engasertib data published in The New England Journal of Medicine.
This recognition validates the strength of the science, the rigor behind the work, and the potential impact for the HHT community.
Thank you to our team, our investigators, and the patients who made this possible.
We now move into the next phase with clarity and confidence as we advance toward our Phase 3 study in 2026.”
Stay updated with Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis